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Abstract
Ecotin is a serine protease inhibitor produced by hundreds of microbial species, including
pathogens. Here we show, that ecotin orthologs from Escherichia coli, Yersinia pestis,
Pseudomonas aeruginosa and Leishmania major are potent inhibitors of MASP-1 and
MASP-2, the two key activator proteases of the complement lectin pathway. Factor D is
the key activator protease of another complement activation route, the alternative pathway.
We show that ecotin inhibits MASP-3, which is the sole factor D activator in resting human
blood. In pathway-specific ELISA tests, we found that all ecotin orthologs are potent lectin
pathway inhibitors, and at high concentration, they block the alternative pathway as well. In
flow cytometry experiments, we compared the extent of complement-mediated opsonization
and lysis of wild-type and ecotin-knockout variants of two E. coli strains carrying different
surface lipopolysaccharides. We show, that endogenous ecotin provides significant protec-
tions against these microbicidal activities for both bacteria. By using pathway specific
complement inhibitors, we detected classical-, lectin- and alternative pathway-driven com-
plement attack from normal serum, with the relative contributions of the activation routes
depending on the lipopolysaccharide type. Moreover, in cell proliferation experiments we
observed an additional, complement-unrelated antimicrobial activity exerted by heat-inacti-
vated serum. While ecotin-knockout cells are highly vulnerable to these activities, endoge-
nous ecotin of wild-type bacteria provides complete protection against the lectin pathway-
related and the complement-unrelated attack, and partial protection against the alternative
pathway-related damage. In all, ecotin emerges as a potent, versatile self-defense tool
that blocks multiple antimicrobial activities of the serum. These findings suggest that ecotin
might be a relevant antimicrobial drug target.
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Author summary
Bloodstream infections are major cause of morbidity and mortality in many countries
around the globe. As the number of multi-drug resistant pathogenic strains is growing, it
is urgent to identify their virulence factors and unveil the corresponding mechanisms of
action that enable the pathogen to avoid potent immune response. A microbial inhibitor
of serine proteases, ecotin was previously implicated in protecting various pathogenic bac-
teria and eukaryotic Leishmania species against the host immune system by inhibiting leu-
kocyte elastase. However, the interaction of ecotin with the complement system, which
provides a first line defense against pathogens, remained unexplored. We found that eco-
tin blocks activation of the complement lectin pathway by inhibiting its key activator
enzymes, MASP-1 and MASP-2. Furthermore, by inhibiting MASP-3, ecotin also disrupts
a fundamental link between the lectin- and the alternative pathways. We provide evidence
that E. coli cells devoid of ecotin are extremely vulnerable to complement-mediated lysis
and they are also potently killed by some complement-independent antimicrobial factors
of human serum. These findings could explain the observations of other research groups
reporting that ecotin is crucial for the survival of pathogenic microbes in the host.
Our results therefore also highlight ecotin as a potential target of future antimicrobial
therapies.
Introduction
Ecotin is a canonical serine protease (SP) inhibitor first isolated from Escherichia coli [1].
Three unique features provide ecotin with unusually broad specificity, yet high affinity. Ecotin
has: i) a “one-size-fits-all” methionine P1 residue [2] acceptable for the S1 pocket of many dif-
ferent SPs; ii) a peculiar binding mechanism whereby the ecotin homodimer “chelates” two
SPs, each being tweezed between the primary binding site of one monomer and the secondary
binding site of the other one [3,4] and iii) structural plasticity [5] enabling accommodation to
a large set of SPs having different binding surfaces. Ecotin inhibits all three major pancreatic
SPs, trypsin, chymotrypsin and elastase, and its function was first assumed to protect E. coli in
its natural habitat, the colon [1]. Later, ecotin was shown to inhibit several plasma SPs, such as
activated coagulation factor X (fXa) [6] and activated coagulation factor XII (fXIIa), as well as
plasma kallikrein [7], but none of these enzymes were considered as physiologic targets.
Since then, ecotin orthologs were found in several microbes including human pathogens,
such as Yersinia pestis¸ Pseudomonas aeruginosa and Burkholderia pseudomallei [8,9] and even
in eukaryotic organisms such as the pathogenic protozoa Trypanosomatida, including Leish-
mania major [10]. Ecotin orthologs from E. coli, Y. pestis, and P. aeruginosa were shown to
inhibit neutrophil elastase (NE) secreted by neutrophils and macrophages during inflamma-
tion, and this activity was interpreted as a potential defense mechanism [11].
The complement system (CS) belongs to the humoral arm of the innate immune system
and it is among the first defense lines against pathogenic microbes. It can be activated through
three pathways, the classical (CP), the lectin (LP) and the alternative pathway (AP) [12]. The
activity of all three pathways rely on specific SPs. Key enzymes of the LP are mannan-binding
lectin (MBL)-associated serine protease (MASP)-1 and -2 [13], while MASP-3 is responsible
for the activation of pro-factor D (pro-FD), the zymogen of the key AP-activating enzyme, fac-
tor D (FD) [14]. Activation of the LP and the AP is independent from the slowly developing
adaptive immune response, therefore these two pathways can unleash an immediate attack
Ecotin protects bacteria against human serum-mediated lysis
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against invading microbes [15]. Accordingly, LP- and AP-inactivating capacity could provide
the pathogens with substantial advantage during colonization of the host.
Interestingly, although the CS is a major, SP-dependent antimicrobial defense arm [15,16],
ecotin has not been assessed as a CS-inhibitor. We studied the mechanism of action of ecotin
in the past [17,18] and are investigating the molecular mechanisms of complement activation
in the present [14,19,20]. When the crystal structures of our in vitro evolved, monospecific
Schistocerca Gregaria Protease Inhibitor-related MASP inhibitors, (SGMI)-1 and SGMI-2
were solved in complex with MASP-1 and MASP-2, respectively [21], it revealed that the
SGMIs and ecotin share analogous intramolecular interactions stabilizing the protease binding
loop. Therefore, we tested E. coli ecotin as a LP inhibitor, and this has subsequently lead to the
comprehensive study described here. This revealed that recombinant E. coli, Y. pestis, P. aeru-
ginosa and L. major ecotin orthologs inhibit MASP-1-, MASP-2 and MASP-3 with varying rel-
ative potencies, while all four ecotin orthologs block LP-activation in normal human serum
(NHS) with high and equal efficiency. We also demonstrated that E. coli ecotin inhibits LP-
activation in mouse and rat sera as well.
Factor D (FD) is the initiator of the AP, and we have recently revealed that MASP-3 is the
exclusive activator of pro-FD in resting human blood [14,22]. Here we show that E. coli ecotin
readily blocks MASP-3-driven pro-FD activation. Using wild type E. coli cells and their deriva-
tives lacking the eco gene (ecotin KO), we also show that endogenous ecotin protects bacteria
against the attack of the LP and the AP, as well as against a complement-independent, heat
resistant antimicrobial mechanism of heat-inactivated serum (HIS). All these findings
unequivocally demonstrate that after 36 years of its discovery, ecotin emerges as a potent
microbial defense factor modulating the immune response of the host by targeting several key
proteases of the immune system. Accordingly, ecotin could be considered as a relevant antimi-
crobial drug target.
Results
Binding affinities of the four ecotin orthologs to the catalytic fragments of MASP-1, MASP-2
and MASP-3 have been determined in the form of dissociation constants, which, for reversible
inhibitors are referred to as equilibrium inhibition constant (KI) values. The values shown in
Table 1 were measured as explained briefly below. In a series of samples increasing concentra-
tion of inhibitor was mixed with a preset concentration of enzyme, and after reaching binding
equilibrium, the free enzyme concentration was determined through measuring the residual
enzyme activity by adding an appropriate substrate. The obtained dose response curve was fit-
ted to the appropriate kinetic model as explained in the Materials and methods section. The
lower the KI value the higher the affinity is, and the differences can span orders of magnitudes.
Therefore, for easier comparison of the affinities, we also illustrated them as -log10 of the KI
values in Fig 1. Some of the measurements delivered apparent KI values. For calculating the
corresponding genuine KI values, we determined the KM values for each MASP enzyme-sub-
strate pair (Fig 2.) (see Materials and methods).
Ecotin orthologs are from weak to moderate inhibitors of MASP-1
From the four orthologs, P. aeruginosa ecotin has a 34 nM binding affinity towards MASP-1.
On the other hand, Y. pestis, L. major and E. coli ecotin orthologs are weak MASP-1 inhibitors
with KI values in the 10−5–10−6 M range (Fig 1, Table 1), the E. coli inhibitor having a 4.2 μM
KI. In a surface plasmon resonance study, Gaboriaud et al. reported no detectable interaction
between E. coli ecotin and MASP-1 [23]. The highest MASP-1 analyte concentration they
Ecotin protects bacteria against human serum-mediated lysis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008232 December 20, 2019 3 / 33
applied was below the KI determined in this study, therefore there is no conflict between the
two observations.
Ecotin orthologs are potent MASP-2 inhibitors
Ecotin orthologs are potent inhibitors of MASP-2 with KI values in the 10−8–10−9 M range
(Fig 1, Table 1). E. coli ecotin inhibits MASP-2 with a KI of 11 nM, which is close to the SPR-
based KD value of 24.7 nM reported by Gaboriaud et al. [23]. Importantly, most ecotin ortho-
logs are as good, or even better MASP-2 inhibitors than SGMI-2, a monospecific, high-affinity
inhibitor of the enzyme we developed previously via directed evolution [21].
Ecotin orthologs are highly potent MASP-3 inhibitors
Except Y. pestis ecotin, which has a KI value of 8.0×10−7 M, the other three orthologs are highly
potent inhibitors of MASP-3 with KI values in the 10−9–10−10 M range (Fig 1, Table 1). E. coli
ecotin, with its 0.5 nM KI value, is a ~20-fold more efficient MASP-3 inhibitor than TFMI-3,
our monospecific MASP-3 inhibitor developed by phage display [14]. Previously, no natural
MASP-3 inhibitors have been identified. Our findings suggest that by inhibiting MASP-3, eco-
tin expressing microbes could disrupt the activatory connection between the LP and the AP
[14]. The 3–4 orders of magnitude higher inhibitory potency of the tested ecotin orthologs on
MASP-2 and MASP-3 versus MASP-1 might reflect the higher evolutionary conservation of
MASP-2 and MASP-3, which are present in all vertebrates, while MASP-1 is apparently miss-
ing from birds and most fish [24–26].
It is worth noting that, by using SPR, Gaboriaud et al. measured a much weaker, 600 nM
affinity between E. coli ecotin and MASP-3 [23]. An important difference between the two
experiments is that they used a single MASP-3 SP domain construct, which lacked even the
SP-structure stabilizing activation peptide. In this study, we used a MASP-3 catalytic fragment
construct containing two complement control protein (CCP) modules connected to the SP
domain through the activation peptide. The observed thousand-fold difference in affinities
Table 1. KI values of four ecotin orthologs, SGMI-2 and TFMI-3 towards all three MASP enzymes. The ecotin-MASP affinities in Table 1 were measured at thermody-
namic equilibrium as described in the Materials and methods. For tight-binding inhibition assays, enzyme and inhibitor concentrations need to be low, close to the KI
value, and reaching the equilibrium requires several hours-long incubation. Then, small synthetic substrates are added, and their conversion rates report on the concentra-
tion of the free enzyme. In these short readout time assays the small substrates compete only with the relatively high-off-rate inhibitors and in this case the measured appar-
ent KI value needs to be corrected with KM (see KM values in Fig 2). On the other hand, small substrates do not compete with the low off-rate tight-binding inhibitors for
enzyme binding.
Inhibitor KI (M)
MASP-1 MASP-2 MASP-3
E. coli ecotin 4.2 ± 0.3�10−6, a 1.1 ± 0.1�10−8, a 5.2 ± 0.3�10−10
Y. pestis ecotin 3.5 ± 0.17�10−5, a 2.2 ± 0.1�10−9, a 8.0 ± 0.3�10−7, a
P. aeruginosa ecotin 3.4 ± 0.2�10−8, a 7.6 ± 0.0�10−8, a 9.6 ± 0.8�10−9, a
L. major ecotin (ISP2) 2.7 ± 0.2�10−6, a 8.8 ± 0.6�10−9, a 4.1 ± 1.0�10−9
SGMI-2 N.D.b 6.0�10−9, b 5.2 ± 0.3�10−6, c
TFMI-3 N.D.d 7.5 ± 0.3�10−5, d 1.1 ± 0.1�10−8, d
Data are the average of at least two independent measurements ± SEM. N.D. No inhibition could be detected.
aData was corrected for competition with the synthetic substrate (see details in Materials and methods).
bData from [21].
cData from [13].
dData from [14].
https://doi.org/10.1371/journal.ppat.1008232.t001
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should correspond to the more stable, native structure of the MASP-3 SP domain in our
experiments.
E. coli ecotin inhibits MASP-3 through a “slow-binding” mechanism, and
blocks MASP-3-driven pro-FD conversion in vitro
The ecotin-MASP KI values in Table 1 were measured at thermodynamic equilibrium using
small synthetic substrates. These values do not necessarily predict how efficiently ecotin would
compete with pro-FD, the large natural substrate of MASP-3, which could bind the enzyme
stronger than small substrates. To test this, first we applied a chromatography-based assay
using purified recombinant proteins [22] and measured how E. coli ecotin hinders pro-FD
conversion. Low sensitivity of the method required high enzyme and inhibitor concentrations,
which facilitate the rapid attainment of equilibrium. We therefore applied short incubation
time. While ecotin inhibited the pro-FD conversion in a concentration-dependent manner, it
was only slightly more efficient than TFMI-3, which has 20-fold lower affinity (Fig 3). Extend-
ing the pre-incubation time between MASP-3 and ecotin significantly increased the binding
Fig 1. Ecotin orthologs from pathogenic microbes inhibit all three MASP enzymes. Affinities of the four ecotin orthologs as well as SGMI-2 and
TFMI-3 toward MASP-1 (light grey bars), MASP-2 (black bars) and MASP-3 (dark grey bars) are shown as–log10(KI) (M) values. Asterisks (�) indicate
that no inhibition could be detected.
https://doi.org/10.1371/journal.ppat.1008232.g001
Ecotin protects bacteria against human serum-mediated lysis
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affinity, which, in agreement with the 0.5 nM equilibrium KI value (Table 1), resulted in a stoi-
chiometric linear titration (Fig 4). This incubation time dependence revealed a slow-binding
complex formation mechanism. Slow-binding, which is quite common for high-affinity com-
plexes, suggests that the structure of the enzyme and/or the inhibitor needs to go through a
slow conformational change during the maturation of the complex.
E. coli ecotin inhibits activation of pro-FD in NHS
We also tested how E. coli ecotin inhibits pro-FD conversion in NHS using an assay format
already described [14,22]. Briefly, the assay was developed for in situ detection of the pro-FD
converting capacity of plasma or serum samples. As these complex biological samples contain
many different proteins including endogenous pro-FD and FD, the assay relies on recombi-
nant, fluorescently labeled pro-FD added to the plasma or serum sample. The kinetics of the
conversion was followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) combined by measuring the fluorescence intensity of the pro-FD and/or FD
band. For testing how ecotin can block endogenous pro-FD conversion, the inhibitor was pre-
Fig 2. KM values of Z-L-Lys-SBzl on MASP-1 (A), MASP-2 (B) and MASP-3 (C) were determined. The KM values of MASP-1, MASP-2 and MASP-3
for Z-L-Lys-SBzl are 334μM, 618μM and 125μM, respectively. Symbols represent the average of three independent measurements. Error bars represent
the SEM. The Hill equation was fitted to the data. The KM values are given in μM ± the standard error.
https://doi.org/10.1371/journal.ppat.1008232.g002
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incubated with the serum for 10 minutes before labeled pro-FD was added. In accordance
with the previously mentioned slow-binding mechanism, thermodynamic equilibrium
between MASP-3 and ecotin could not be reached, and in the first hour, the rate of pro-FD
activation was almost unaffected. However, pro-FD activation was almost completely inhibited
after ~6 hours indicating formation of the high-affinity equilibrium ecotin-MASP-3 complex.
While 1 μM TFMI-3 prolonged the 3 hour serum half-life of pro-FD to ~40 hours [14], 1 μM
of the slow-binding E. coli ecotin prolonged it to 10 hours (Fig 3).
E. coli ecotin is a moderate inhibitor of FD and of the AP-type C3
convertase, C3bBb
We tested whether E. coli ecotin inhibits FD and/or C3bBb, the two activator proteases of the
AP. FD-inhibition was measured in a simple photometric enzyme-inhibition assay using the
small molecule synthetic substrate, Z-Lys-SBzl (see Materials and methods), and the corre-
sponding KI value is 4.06 μM.
Combined inhibitory activity of ecotin on FD and C3bBb was tested in an SDS-PAGE
based densitometry-analyzed C3-cleavage assay, and it was compared to that of the small mol-
ecule pan-specific complement inhibitor, FUT-175. In this assay, isolated FB and C3b serve as
components for the formation of the pro-convertase, C3bB, isolated C3 serves as substrate,
and C3bBb formation and C3-clevage is initiated by adding isolated FD to the mixture con-
taining no inhibitor (positive control), 10 μM ecotin, or 100 μM FUT. In the positive control
approximately 45% of the C3 was cleaved to C3b and C3a in the first 10 minutes (Fig 5A and
5E), after which no further cleavage occurred due to the short half-life of C3bBb. Therefore,
we quantified and compared the C3b-contents of the 10-minute samples (Fig 5F). At 10 μM
concentration E. coli ecotin reduced C3b-formation by 20% (Fig 5C and 5F), while 100 μM
FUT-175 exerted 80% inhibition (Fig 5D and 5F).
E. coli ecotin is a weak inhibitor of C1s while it is inactive on C1r
By using catalytic fragments of C1s and C1r and their appropriate synthetic substrates, we
tested how ecotin inhibits these key enzymes of the CP. We could not detect any inhibition of
Fig 3. E. coli ecotin inhibits the activation of pro-FD to FD in NHS. Its efficiency is compared to that of our already
published in vitro evolved MASP-3 inhibitor, TFMI-3. 1 μM ecotin increases the half-life of fluorescently labeled pro-
FD in NHS from 3 hours to 10 hours, while 1 μM TFMI-3 prolongs that to ~40 hours.
https://doi.org/10.1371/journal.ppat.1008232.g003
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PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008232 December 20, 2019 7 / 33
C1r, while ecotin inhibited C1s with a 25.15±4.45 μM KI value representing a very weak inhibi-
tion. These findings are in agreement with previous SPR-based results of Gaboriaud et al. [23]
who immobilized ecotin on the chip and by injecting up to 2 μM C1s or C1r catalytic frag-
ments, did not detect any interaction.
Effects of ecotin orthologs on the three complement pathways in NHS
We measured the inhibitory potency of ecotin variants on the three individual CS pathways
using NHS.
In accordance with their MASP inhibition profile, ecotin orthologs readily blocked man-
nan-triggered LP-driven C3-deposition in 2% NHS (Fig 6A). Our second-generation in vitro
evolved MASP-2 inhibitor, SGMI-2 [13,21] was used as an internal reference to assess relative
Fig 4. E. coli ecotin inhibits the MASP-3 driven pro-FD conversion. E. coli ecotin was shown to be a high-affinity inhibitor of MASP-3 (see Table 1)
in a small synthetic substrate-based in vitro enzyme-inhibition test, where enzyme and inhibitor reached thermodynamic equilibrium. We measured
how efficiently ecotin inhibits MASP-3 under non-equilibrium conditions by competing with pro-FD, the natural substrate of the enzyme. We found
that ecotin inhibits MASP-3 driven pro-FD conversion in a concentration-dependent manner (■), but only slightly more effectively than the 20-fold
lower affinity MASP-3 inhibitor TFMI-3 (▲) (see Table 1). After pre-incubating ecotin with MASP-3 to approach thermodynamic equilibrium, the
interaction of the two proteins became stronger and stoichiometric (●) in accordance with the subnanomolar KI value (see Table 1). This suggests that
the interaction reaches equilibrium slowly. Data points are the average of two independent measurements. Error bars represent the SEM. Dotted lines
are used to visually emphasize the trends.
https://doi.org/10.1371/journal.ppat.1008232.g004
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LP-inhibitory efficiencies of the inhibitors. The IC50 value range of the ecotin orthologs is 84–
190 nM, the highest value being essentially identical with that of SGMI-2 (194 nM) (Fig 6D).
Overall, this is in accordance with the KI values of the inhibitors towards MASP-2. While the
IC50 range is narrow, it is notable, that the most efficient LP inhibitor is P. aeruginosa ecotin,
which has the best-balanced MASP inhibitory profile. While the other three orthologs are
stronger MASP-2 inhibitors, they are significantly weaker MASP-1 inhibitors. Apparently,
inhibitors having moderate affinities toward both MASP-1 and MASP-2, can be similarly or
more efficient LP inhibitors than more specific, high-affinity MASP-2 inhibitors. We observed
the same phenomenon for our first-generation sunflower trypsin inhibitor (SFTI) related
MASP inhibitor (SFMI) compounds [27]. All ecotin orthologs provided complete LP-inhibi-
tion in the low micromolar range.
LPS- or zymosan-triggered, AP-driven C3-deposition was measured in 16.7% (6-fold
diluted) NHS representing a serum concentration about 8-fold higher than the one used for
the CP- and LP-activation assays. All ecotin orthologs exerted potent AP-inhibition in this
test, but required a higher, 10 μM inhibitor concentration (Fig 6F). This result is in agreement
Fig 5. E. coli ecotin inhibits FD-driven C3bBb-formation and C3bBb-mediated C3b-production. Approximately 45% of C3 was cleaved when no
inhibitor was present (positive control) (A). When no FB and FD were present, no C3-cleavage occurred (negative control) (B). In (C) the sample
contained 10 μM E. coli ecotin, while in (D) 100 μM FUT. As the AP-type C3bBb C3-convertase has a short half-life, no C3-clevage occurs after 10
minutes (E), hence, we compared the amounts of C3b generated in 10 minutes after adding FD (F). At 10 μM, E. coli ecotin decreased the production
of C3b by 20% (C, F), while at 100 μM, FUT, the small-molecule general complement-inhibitor, decreased C3b-production by 80% (D, F).
https://doi.org/10.1371/journal.ppat.1008232.g005
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with the above mentioned synthetic substrate based and SDS-PAGE based observations,
where ecotin was shown to be a micromolar FD-inhibitor, and a moderate inhibitor of de novo
C3bBb production as well as of C3bBb-driven C3b production (Fig 5F).
As we showed that E. coli ecotin is a very weak C1s inhibitor, which does not inhibit C1r at
all, we already anticipated that this ecotin ortholog will not inhibit the CP. This was verified
and we also found that none of the ecotin orthologs inhibited IgG-triggered CP-driven
C3-deposition in 2% NHS (Fig 7). This indicates that the other ecotin orthologs are also inef-
fective against C1s and C1r.
Ecotin orthologs do not inhibit the C4b2a-type C3 convertase
Potent LP-inhibitory activity of all tested ecotin orthologs demonstrated that ecotin remains
functional in NHS i.e. it is not degraded by any serum protease. As the CP- and the LP-inhibi-
tory ELISA test conditions differ only in the immobilized target, all ecotin orthologs must be
Fig 6. Ecotin is shown to inhibit LP- and AP-activation in human, and LP-activation in mouse and rat serum. C3-deposition on mannan-coated
plates from dilute sera was measured as a function of inhibitor-concentration. All four tested ecotin orthologs are equally potent inhibitors of LP-
activation in 50-fold diluted NHS. Their effects are comparable to that of our previously evolved selective MASP-2 inhibitor, SGMI-2. (A) E. coli ecotin
inhibits the LP in analogous tests using 60-fold diluted pooled sera of C57BL/6 and BALB/c mice. (B), and 60-fold diluted serum of Wistar rat (C). IC50
values for human and rodent serum are listed in (D) and (E), respectively. In the about 10-fold more concentrate, 6-fold diluted NHS used for the
alternative pathway inhibition tests, 10 μM of the ecotin orthologs provide ortholog-specific, but significant inhibition, L. major ecotin being the most
potent one (F). Symbols represent the average of at least two measurements. Error bars represent the SEM.
https://doi.org/10.1371/journal.ppat.1008232.g006
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present in the CP-assay in functional form. Lack of CP-blocking activity therefore clearly dem-
onstrates that ecotin orthologs are inactive against the C4b2a-type C3 convertase.
E. coli ecotin is a potent LP inhibitor in rat and mouse serum as well
To test whether ecotin can block mannan-triggered LP-activation in other mammalian spe-
cies as well, we used pooled sera of C57BL/6 and BALB/c mice and an individual serum sam-
ple of a Wistar rat, and tested the inhibitory effect of E. coli ecotin in C3-deposition ELISA
tests. E. coli ecotin proved to be effective LP inhibitor in all three tests with IC50 values of 16
nM, 30 nM and 16 nM in C57BL/6 or BALB/c mice and Wistar rat, respectively (Fig 6B, 6C
and 6E). The results reveal that the physiologic and pathologic roles of LP inhibitory activity
of ecotin can be readily tested in these animal models. Moreover, cross-species activity of
ecotin suggests an ancient role in microbial defense that could manifest in broad phylogenic
groups of hosts.
Fig 7. Ecotin orthologs do not inhibit the classical pathway (CP). CP was triggered from 50-fold diluted NHS on IgG coated plates. Symbols
represent the average of four parallel measurements. Error bars represent the SD.
https://doi.org/10.1371/journal.ppat.1008232.g007
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Endogenous ecotin protects bacteria in NHS against C3-deposition,
membrane attack complex (MAC) formation and MAC-mediated cell-
killing
We tested how endogenous ecotin protects bacteria against complement-mediated attack of
NHS by comparing wild type and ecotin KO variants of two E. coli strains (ATCC 23505 and
ATCC 12014) having different lipopolysaccharide (LPS) surfaces. Briefly, wild type or ecotin
KO bacteria were incubated in 1–16% NHS for 30 min and deposition of activated C3 frag-
ments and C5b-9 were measured by flow cytometry. Gating strategy is shown in a representa-
tive case in Fig 8. Cell death was also monitored by propidium iodide (PI) staining and
proliferation-based viability tests.
The O-antigen of the ATCC 23505 strain is a mannan homopolymer [28], which activates
the complement LP [29]. On the other hand, the more typical O-antigen (O55) of the smooth
LPS of ATCC 12014 is composed of repeating pentasaccharide units lacking mannan groups
but containing several acetylated carbohydrate components [30].
C3 and C5b-9-deposition was significantly higher on the ecotin KO versions of the two
strains in terms of the mean fluorescence intensity (MFI) values of the C3 positive population
and the ratio of C5b-9/PI positive cells (Fig 9A, 9C, 9D and 9F). The percentage of C3 positive
cells was also higher in the ecotin KO versions of the two strains at lower serum concentra-
tions. At the highest NHS concentration (16%) the percentage of C3 positive cells reached a
plateau in both the wild type and ecotin KO samples. In further experiments and analyses the
C3 MFI values of the C3 positive cells were determined and compared. In above 4% NHS, the
lysis of the ecotin KO cells was so intense, that large amount of DNA was detected in the cell
supernatant (Fig 10), and the ratio of the C5b-9/PI positive cells topped or even decreased
Fig 8. Gating strategy for analyzing C3 and C5b9 deposition by flow cytometry. Thresholds and gating on bacteria
population on FSC-SSC plots was set up and verified by analyzing signals of 0.2 μm filtered buffer. Even the filtered
buffers contained low amount of particles in the size range of bacteria (A) causing low level of inhomogeneity in the
bacterial gate. A representative C3 staining of 2% NHS treated ATCC 23505 cells (filled grey histogram untreated cells,
dashed line wild type cells, solid black line ecotin KO cells) is shown on panel B. Fluorescence intensity was measured
on 20,000 cells captured inside the bacteria gate and C3+ marker was set on the negative control untreated sample.
Because of the biasing effect of the few non-bacterial particles in the bacteria gate, the statistical analysis (MFI) of
C3-deposition was conducted on the cells under the C3+ marker. Control samples had no event in this region (B).
C5b9/PI positive cells were determined by double staining of the cells after treatment. 20,000 cells in the bacteria gate
were analyzed, quadrants were set on the untreated, labeled samples. Sample preparation alone induces some cell death
(PI positivity) in the samples. Percentage of C5b-9/PI positive cells inside bacteria gate (upper right quadrant) was used
for data analysis (C).
https://doi.org/10.1371/journal.ppat.1008232.g008
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(Fig 9C and 9F) indicating that the highest-labeled population disintegrated. In contrast, on
the wild type cells, only low level of C3b and C5b-9 was detected up to 8% NHS for the ATCC
12014 strain and up to the highest tested NHS concentration of 16% for the ATCC 23505
strain suggesting a highly efficient protective role of ecotin enabling only a sub-lethal level of
Fig 9. Endogenous ecotin protects E. coli against C3 and C5b-9-deposition from NHS. The extent and the initiating pathway of CS activation were
studied on two wild type and ecotin KO coli strains, the polymannan LPS carrying ATCC 23505 and the smooth LPS containing ATCC 12014. Cells
were treated with increasing concentrations of NHS and labeled for deposited C3 fragments, and C5b-9 as described in Materials and methods. Mean
fluorescence intensity (MFI) values of C3 positive cells (A, D) and percentage of C5b-9/PI positive cells inside the bacteria FSC-SSC gate were
determined and is shown (C, F). Cells were treated with 2% NHS containing the indicated inhibitors, and the MFI of deposited C3 was determined as
for panel A and D. MFI of deposited C3 without inhibitor was considered 100% complement activity (B, E). Data represent median +/- SD of three
independent experiments. MFI of the C3-positive and C5b-9/PI positive ATCC 23505 ecotin KO cells was orders of magnitude higher than that of the
wild type cells (A, C). This strain should trigger the LP, and indeed, SGMI-1 and SGMI-2, inhibiting MASP-1 and MASP-2, respectively, as well as
exogenously added ecotin provided complete inhibition, while the anti-C1q mAb had no effect. The broad-specificity protease-inhibitor, FUT-175 was
included as a control (B). Similar trends were found with the ATCC 12014 cells. This strain is less intensely attacked by the complement, and while it is
also protected by its endogenous ecotin, the ratio of C3 MFI values and percentage of C5b-9/PI positive cells are smaller (D, F). All exogenously added
inhibitors decreased C3-deposition on ATCC 12014 ecotin KO cells, but SGMI-1 and anti-C1q mAb were the most efficient. Therefore, this strain was
attacked by all three, but dominantly by the classical and the alternative pathway (E).
https://doi.org/10.1371/journal.ppat.1008232.g009
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MAC formation (Fig 9C and 9F). In fact, this low level MAC formation could be of utmost
importance as it could open an exit route for the periplasmic ecotin through the outer mem-
brane to reach the site of the surface-localized complement attack. The observed difference in
the two wild type strains is apparently due to the different relative contributions of the three
CS pathway to the attack, as explained below.
To assess which CS pathways are in action against the ecotin KO cells, we used exogenously
added selective inhibitors: SGMI-2, which blocks only the LP [13], SGMI-1, which blocks both
the LP and, when applied at higher concentrations, the LPS-triggered AP [13,19] and an anti-
C1q monoclonal antibody (mAb) (MW1828, Sanquin), which blocks the CP. Ecotin was also
applied exogenously as a control to test whether it provides comparable protection to that of
the endogenous periplasmic inhibitor present in the wild type bacteria. We conducted these
tests both in the context of the above mentioned C3-deposition assay as well as with the cell
proliferation assays described below.
Briefly, in the proliferation-based cell-killing assay, constant amount of mid-log phase cells
was treated for 1h with diluted serum either lacking or containing exogenously added inhibi-
tors. The bacteria were then transferred into large excess of broth and the optical density (λ =
600 nm) was measured after 5h incubation.
In agreement with the C5b-9-deposition assay, the ecotin KO ATCC 23505 strain was effi-
ciently attacked and killed by the serum, as almost no viable cell remained after an exposure to
as low as 1% NHS. On the other hand, endogenous ecotin of the wild type ATCC 23505 strain
provided perfect protection in a broad range of serum dilution up to 16% (Fig 11A).
We tested whether increased serum-susceptibility of the ecotin KO ATCC 23505 and
ATCC 12014 cells is due only to the lack of endogenous ecotin. To do so, we transformed
these cells with an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible vector to restore
Fig 10. Intense NHS-driven cell-lysis is detected by DNA-content of cell supernatants. We examined MAC
formation both by C5b-9 specific antibodies and by propidium iodide (PI) to identify bacteria killed by MAC-driven
cell lysis. In several samples, where cells were treated with above 4% NHS, the C5b-9 MFI values of the C5b-9/PI
positive cells topped or even decreased (Fig 9C and 9F) indicating some artefacts. Here we show that the supernatants
of these cells contain large amounts of DNA suggesting that the highest-labeled C5b-9/PI positive population has been
disintegrated. Supernatants obtained during the preparation for flow cytometry experiments were applied onto agarose
gel and DNA was detected with SYBR Green. No significant amounts of DNA leaked from wild type ATCC 23505 cells
upon incubation with serum up to 16% NHS (A), while its ecotin KO derivative already lysed in as low as 1% NHS (B).
The supernatant of ATCC 12014 cells contain detectable (C), while that of its ecotin KO derivative significant amount
(D) of DNA upon treatment with 8% or 16% NHS. The % values indicate the NHS concentration the cells were treated
with.
https://doi.org/10.1371/journal.ppat.1008232.g010
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periplasmic ecotin expression. Constructing the expression vector and measuring periplasmic
ecotin levels of the cells is described in the Materials and methods. Briefly, ecotin levels were
measured through chymotrypsin inhibitory activity of the isolated periplasmic fraction as fol-
lows: 20 nM final concentration of bovine chymotrypsin was mixed with serial dilutions of
periplasmic fractions and the dilution corresponding to 50% enzyme inhibition was deter-
mined. We verified that the periplasm of ecotin KO cells does not contain ecotin. Isolated
periplasmic fraction of wild type cells readily inhibited chymotrypsin. The periplasm of trans-
formed but non-induced cells showed hardly detectable chymotrypsin inhibitory activity. Eco-
tin levels in the periplasmic fraction of transformed and IPTG-induced ATCC 12014 ecotin
KO cells exceeded the wild type level 2.6-fold, while the corresponding ratio for the ATCC
23505 ecotin KO cells was 1.5-fold. Therefore, periplasmic ecotin level was restored or slightly
increased over the wild type level in both strains.
Most importantly, in the ATCC 23505 ecotin KO strains, endogenously expressed ecotin
perfectly restored wild type phenotype. Without induction, the vector-carrying ecotin KO cells
were as susceptible to cell-killing as the untransformed ecotin KO cell. In contrast, IPTG-
induced ecotin expression rescued these cells providing them with a level of protection practi-
cally identical with that of the wild type (Fig 11A).
The flow cytometry experiments above demonstrated that the ATCC 23505 bacteria were
attacked only by the LP, as both SGMI-1 and SGMI-2 could completely block C3-deposition,
while the anti-C1q mAb provided no protection (Fig 9B). Exogenous ecotin also provided full
protection in agreement with the fact that wild-type ATCC 23505 cells and the rescued KO
cells were completely protected by their endogenous ecotin (Figs 9B and 11A). The cell prolif-
eration experiments yielded the same results: all LP-inhibitory compounds provided full pro-
tection for the cells, while the anti-C1q mAb had no activity (Fig 12A).
Likewise, the flow cytometry measurements above showed that the ATCC 12014 bacteria
were also attacked by the complement system, but, in terms of deposited C3, at a tenfold lower
level (Fig 9D), and through different mechanisms (Fig 9E). Anti-C1q mAb and SGMI-1 pro-
vided almost complete protection against C3-deposition approaching the level achieved by the
broad-specificity protease inhibitor FUT-175 [31] (344960, Sigma-Aldrich), while SGMI-2 had
much lower protecting effects (Fig 9E) demonstrating that LP-activation on this strain is negli-
gible. On the other hand, high efficiency of the anti-C1q mAb treatment identified an essential
role of CP activation, and the observed drop in C3-deposition can be interpreted as the can-
celled contribution of the CP, plus the CP-triggered positive feedback loop provided by the
AP, the latter one generating up to 90% of the deposited C3b [32]. High efficiency of SGMI-1
(Fig 9E) cannot be explained by LP-inhibition, as we already concluded that LP was hardly
triggered. However, it is in agreement with our previous finding that at the high concentration
applied here, SGMI-1 is a strong inhibitor of LPS-triggered AP activity [19]. In all, high effi-
ciency of SGMI-1 suggests that it inhibits both spontaneous AP-activation as well as the CP-
triggered AP feedback loop.
The cell proliferation tests provided coherent results: endogenous ecotin of the wild type
ATCC 12014 strain, that does not inhibit CP-activation, provided significant, but only partial
protection for the bacteria (Fig 11B), most probably by partial inhibition of the AP amplifica-
tion loop. When SGMI-1 or the anti-C1q antibody was added exogenously to the ecotin KO
cells, these provided significantly stronger protection than SGMI-2, which had only a marginal
effect (Fig 12B).
Again, importantly, in the ATCC 12014 ecotin KO strains, endogenously expressed ecotin
perfectly restored wild type phenotype in the cell-killing assay. Without induction, the vector-
carrying ecotin KO cells were as susceptible to cell-killing as the untransformed ecotin KO cell,
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while ecotin expression induction rescued these cells providing them with a level of protection
practically identical with that of the wild type cells (Fig 11B).
Endogenous ecotin protects bacteria against a complement-independent,
heat-stable antimicrobial effector mechanism of serum
As the activity of the CS is heat sensitive, heat-inactivated serum (HIS) was used in the flow
cytometry and cell proliferation assays as a typical negative control serving as a baseline to
deconvolute complement-specific effects. In the flow cytometry assays, as expected, no
C3-deposition was detected from HIS. Yet, based on the cell proliferation assays, and to our
Fig 11. Endogenous ecotin protects bacteria against bactericidal effects of serum. Wild type cells of both strains were more resistant to the
bactericidal effects of serum than their ecotin KO versions. Accordingly, when the ecotin KO cells were provided with the ecotin gene using an IPTG-
inducible vector, non-induced cells behaved as the untransformed, original ecotin KO cells, while 50 μM IPTG-induction restored the resistant, wild
type phenotype in these cells as follows. ATCC 23505 ecotin KO cells and their transformed but non-induced version were killed even by 1% NHS,
while wild type cells and transformed, IPTG-induced ecotin KO cells were completely protected against 16% NHS (A). Up to 4% NHS, endogenous
ecotin provided significant protection for the wild type and the transformed, IPTG-induced ecotin KO ATCC 12014 cells, but at higher NHS
concentration, both the ecotin KO cells, regardless of IPTG-induction, and the wild type cells died (B). We also tested if heat inactivated serum (HIS)
affects viability of these strains. Interestingly, above 4% concentration, HIS eliminated about 50% of the untransformed ATCC 23505 ecotin KO cells
and their transformed but non-induced derivative, while the original wild type and the transformed and IPTG-induced ecotin KO version were
completely protected (C). Wild type and ecotin KO ATCC 12014 cells were practically resistant to HIS, regardless of transformation and IPTG-
induction (D). Results are from three parallel experiments. Error bars represent the SD, asterisks (�) represent p< 0.05 (two-tailed Student’s t-test)
between the OD values of wild type and ecotin KO cells and their derivatives.
https://doi.org/10.1371/journal.ppat.1008232.g011
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great surprise, the polymannan O9 LPS-carrying ecotin KO ATCC 23505 strain was attacked
by HIS in a serum concentration dependent manner (Fig 11C). Lack of deposited C3 frag-
ments verifies that this attack is complement-unrelated. Bactericidal activity of HIS has already
been examined by others [33], but the nature of such effects remained enigmatic. The observed
bactericidal effect could be ameliorated via supplementing the HIS with ecotin or with the
Fig 12. Mechanism of the bactericidal effects investigated by exogenous inhibitors. Just like for C3-deposition in Fig 9, we tested the efficacy of
exogenously added inhibitors also on the bactericidal effect. We used 1% NHS where the observed bactericidal effect of heat-stable factors (see Fig 11C)
is negligible. Exogenously added SGMI-1 and -2, as well as ecotin rescued the ATCC 23505 ecotin KO strain, while anti-C1q mAb exerted minimal
effect (A) supporting the dominant role of LP-activation. ATCC 12014 ecotin KO cells were rescued by the anti-C1q mAb, ecotin and SGMI-1, while
SGMI-2 exerted a minor effect suggesting that all three complement pathways are in action, but the classical and alternative pathways dominate (B). We
also attempted to identify the factors responsible for complement-independent bactericidal effects of 16% HIS. Only ecotin and the general serine
protease inhibitor FUT-175 could diminish this attack (C). Data are from at least two parallel measurements, asterisks (�) representing p< 0.05 (two-
tailed Student’s t-test) when comparing the OD values of samples treated with inhibitors to those of 1% NHS. As data in (C) were obtained from two
parallels, no statistical significance was calculated. Error bars represent the SD.
https://doi.org/10.1371/journal.ppat.1008232.g012
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broad-specificity protease inhibitor FUT-175 [31]. Extraneous ecotin therefore ablated suscep-
tibility of the cells to a bactericidal effect of HIS. However, our monospecific MASP-inhibitors,
SGMI-1, SGMI-2 and TFMI-3 were all ineffective, as were the plasma kallikrein inhibitor
PKSI-527 [34] and the FXIIa-blocking corn trypsin inhibitor [35] (Fig 12C). This inhibitor
panel demonstrates that the complement-unrelated attack is protease-dependent, but is not
driven by the contact system or by any moonlighting activity of the MASP enzymes.
We tested if the observed susceptibility of the ecotin KO ATCC 23505 cells to HIS concen-
tration above 4% was due exclusively to the lack of endogenous ecotin, as explained for the
other cell-killing tests. We found that in the ATCC 23505 ecotin KO strains, endogenously
expressed ecotin perfectly restored wild type phenotype. Without induction, the vector-carry-
ing ecotin KO cells were as susceptible to cell-killing as the untransformed ecotin KO cell. In
contrast, IPTG-induced ecotin expression rescued these cells providing them with the same
level of protection observed for the wild type (Fig 11C).
Discussion
Microbial pathogens evolved a variety of complement evasion strategies. These mainly rely on
the acquisition or expression of complement regulators and inhibitors, or on the degradation
of complement components [36–38], demonstrating that complement inhibition is a crucial
defense mechanism of pathogenic microbes. In this paper, we unequivocally prove that ecotin
inhibits both antibody-independent CS pathways, the LP and the AP, and it also blocks an
apparently complement unrelated antibacterial serum activity. These discoveries place
previous findings of other research groups about ecotin as a potential virulence factor into
completely new context.
Ecotin was discovered 36 years ago in E. coli. By now, ecotin orthologs have been identified
in more than 200 species, and over 40 of these are well-documented opportunistic or obliga-
tory pathogens including Trypanosoma cruzi, Leishmania major, Burkholderia pseudomallei,
Yersinia pestis and Pseudomonas aeruginosa (summarized in Fig 13 and S1 Table). These
updated numbers support the decade-old finding that ecotin genes are more frequent in path-
ogenic species than in non-pathogenic ones [39]. Ecotin producing organisms are widespread
among Bacteria, especially within the Gammaproteobacteria subdivision, which contains
more than a hundred species harboring ecotin orthologs. In this subdivision, the Enterobacter-
iaceae family is particularly rich in known pathogenic species expressing ecotin. Moreover,
several members of the eukaryotic Euglenozoa genus including the human parasites Trypano-
soma brucei and Leishmania major also express ecotin orthologs (S1 Table).
Ecotin has been identified as virulence factor for several pathogenic Gram negative bacteria
such as Yersinia and Burkholderia species and two species of the eukaryotic unicellular patho-
gen, Leishmania as well [8–10,40].
The gastrointestinal pathogen, Yersinia pseudotuberculosis is a close relative of the etiologic
agent of the bubonic and pneumonic plague, Yersinia pestis. When wild type and ecotin KO
Yersinia pseudotuberculosis cells were injected into the bloodstream of mice in 1:1 ratio, after 5
days, the wild type cells were present in about 30-fold excess compared to the ecotin KO cells.
It was hypothesized that the in vivo function of ecotin might be protection from neutrophil-
dependent killing probably by inhibiting neutrophil elastase [8]. Pseudomonas aeruginosa is an
opportunistic pathogen causing chronic lung infections. Its ecotin was found to be sequestered
by the exopolysaccharide, PsI on the bacterial surface and again, it was shown to protect the
cells against neutrophil elastase-mediated elimination of the bacteria [41]. This phenomenon
is in agreement with the findings of others, who found, that ecotin expression is upregulated
in E. coli and P. aeruginosa biofilms [42,43]. Since both pathogens form biofilms in certain
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diseases [44], this might be a mechanism by which ecotin expressing bacteria increase their
protection against antimicrobial effectors of the host. For Burkholderia pseudomallei, the caus-
ative agent of melioidosis, ecotin was shown to be important for intracellular survival of the
bacteria in murine macrophages, most probably by inhibiting several proteases of the early
endosome and allowing for an escape of the intracellular pathogen into the cytosol. Impor-
tantly, compared to the wild type strain, intraperitoneal infection with the ecotin KO strain
leads to increased time to death and greater survival rate of the infected mice [9].
Ecotin orthologs are present in several species of the eukaryotic parasite Trypanosomatidae
family including Trypanosoma cruzi causing Chagas disease, Leishmania major causing zoo-
notic cutaneous leishmaniasis and Leishmania donovani the etiologic agent of visceral leish-
maniasis or kala-azar. While it was shown that Trypanosoma cruzi is attacked by all three
complement pathways, and several parasite proteins were found to attenuate this attack, ecotin
was not identified as a complement inhibitor, but was suggested to protect the cells against
neutrophil elastase and cathepsin G [45,46].
Similarly, all but one publications on Leishmania ecotin orthologs indicated that the main
function of these proteins is protection against intestinal proteases in the gut of the insect
Fig 13. Occurrence of ecotin orthologs in the kingdoms of Eukaryota and Bacteria. Orthologs of ecotin are present in both Eukaryota and Bacteria
kingdoms. More than three hundred species express at least one ecotin homolog. Among eukaryotic species, the Trypanosomatidae, belonging to the
Kinetoplastida class, contain several species that are causative agents of serious and widespread diseases (based on publicly available pathogen databases
(see Materials and methods)), and 12 species of this genus express ecotin homologs (based on the PFAM database https://pfam.xfam.org). Among
Bacteria two classes are exceptionally rich in ecotin expressing species: Bacteroidetes (40 species) and Proteobacteria (158 species). Numbers in bold
indicate how many pathogens exist among the ecotin expressing species in that genera; while those in italic indicate how many pathogens are among all
species in that genera. Figure was made based on PFAM (https://pfam.xfam.org).
https://doi.org/10.1371/journal.ppat.1008232.g013
Ecotin protects bacteria against human serum-mediated lysis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008232 December 20, 2019 19 / 33
vector, or against contact pathway-mediated bactericidal effects of the host [47,48], or down-
regulation of inflammatory monocytes and monocyte-derived cells [49]. We found only a sin-
gle, very recent paper reporting that Leishmania donovani ecotin ortholog LnISP2 is not only a
neutrophil elastase inhibitor, but also a MASP-2 inhibitor [40]. Notably, however, in that
study, recombinant LnISP2 was 50-fold less efficient in providing complete MASP-2 / LP-inhi-
bition, than our recombinant Leishmania major ISP2 ortholog in analogous tests.
In all, we demonstrated that ecotin inhibits i) LP-activation, ii) LPS / zymosan-triggered
AP-activation, iii) MASP-3-based pro-FD activation and iv) an apparently complement-unre-
lated antimicrobial effect of HIS. All these functions of ecotin, as we showed, provide a prolif-
erative advantage for the ecotin harboring cells.
While the molecular mechanism of LP-inhibition is obvious: ecotin potently inhibits
MASP-2, the source of the observed heat-stable bactericidal activity, and thereby the protect-
ing mechanism of ecotin needs to be identified, and the mechanism of ecotin-based AP-inhibi-
tion also requires further investigation.
We showed that E. coli ecotin is a 4 μM FD-inhibitor and that at 10 μM concentration it
could provide up to 75% inhibition of AP-activation triggered by LPS- and zymosan surfaces.
Moreover, in a system containing purified components, we also showed that, at a lower degree,
ecotin blocked FD-driven C3bBb generation and C3bBb-driven C3b generation, demonstrat-
ing that E. coli ecotin is a weak inhibitor of FD, C3bBb, or both. Note, that in the serum tests,
ecotin was pre-incubated with the serum, so it could reach binding equilibrium with the active
FD contents of the serum. In the solution assay no such pre-equilibrium with FD was possible
as the reaction was initiated by FD. Moreover, it is important to note that the above AP-activa-
tion systems are not readily comparable. LPS and zymosan-triggered AP-activation are com-
plex, serum-based assays engaging many complement regulatory proteins. Moreover, AP-
activation in these tests occur on surfaces, and require a de novo C3b-generation phase offering
a level of inhibitory intervention missing from the solution phase AP-convertase generating
system containing an initial C3b pool provided as purified protein. Previously we showed that
MASP-1 is essential for LPS-triggered, but not for zymosan-triggered AP-activation [19]. As E.
coli ecotin is a micromolar MASP-1 inhibitor, this activity might contribute to the inhibition
of LPS-triggered but not to zymosan-triggered AP-activation. As long as the exact molecular
mechanisms of AP-activation on these surfaces remain unknown, it cannot be excluded that
zymosan-triggered AP-activation also relies on a yet to be identified protease, inhibited by
ecotin.
MASP-3 was for long considered as a protease lacking any natural serpin-type or canonical
inhibitor. Accordingly, the most outstanding property of ecotin is its very high inhibitory
potency on MASP-3. As we have recently showed, in resting blood, not perturbed by coagula-
tion or inflammatory processes, MASP-3 is the exclusive activator of pro-FD [14]. As FD is the
AP-initiator enzyme, this MASP-3 function is fundamental, and the outstanding MASP-
3-inhibitory capacity of ecotin suggests an important biologic function. Note, however, that
this ecotin function could not manifest in our AP tests, as in those assays FD was already pres-
ent in the serum in activated form, or was provided as activated, isolated protein.
As mentioned, in the blood, due to the presence of activated MASP-3, FD circulates mostly
in activated form. While systemic control of FD-activation in the blood through complete
MASP-3 inhibition should be possible, it would require the continuous presence of large
excess of ecotin, which is an unlikely situation in microbial infections. On the other hand, inhi-
bition of MASP-3-driven pro-FD activation can be relevant at the much more common loca-
tions of primary infections, which also represent the only niche of normal microbiota, the
periphery, including the mucosae. Several opportunistic pathogens, such as E. coli and P. aeru-
ginosa colonize at first the mucosae, therefore the earliest encounter between the complement
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and the bacteria occurs in this environment. The composition of the complement, the concen-
tration of its components, and therefore the mechanism of complement activation might be
different in the extravascular environments from those in the blood [50–52]. For example, the
level of activated FD at the periphery might be limited by the level of its activators, and if so,
ecotin could provide a major defense mechanism against the AP. A similar difference between
blood and extravascular environments might prevail for the levels of the LP components.
Based on this, we suggest that the potent protective effects of ecotin we demonstrated in dilute
serum against the LP, the AP and a complement-unrelated attack imply similar efficient pro-
tections in mucosal, interstitial and other extravascular environments.
In all, the activities of ecotin revealed here, together with its previously established neutro-
phil and macrophage controlling actions demonstrate, that ecotin blocks or attenuates a pleth-
ora of powerful antimicrobial attacks of the host innate immune system. These versatile innate
immunity-attenuating activities of ecotin might have been evolved in the normal host micro-
biota to provide general protection for the microbes in the mucosa and other extravascular
niches as long as they do not provoke specific IgG-response unleashing (among others) the
ecotin-resistant classical complement pathway. The very same ecotin functions, when com-
bined with other virulence factors, should provide important advantages for pathogens as well.
We believe that all previous studies conducted on the interactions between ecotin-harbor-
ing microbes and their hosts should be revisited and reevaluated in the light of these new
findings. We suggest that ecotin should be put in the focal point of dedicated fundamental
research, and as it can be a potential drug target, the new findings might open novel therapeu-
tic options as well.
Materials and methods
Ethics statement
All studies using human serum were conducted in strict conformity with the WMA Declara-
tion of Helsinki. Experimental protocols were approved by the local ethics committee (permis-
sion number: TUKEB 9190-1/2017/EKU). Informed written consent was obtained for the
isolation of peripheral venous blood from the donors.
All procedures using mouse serum were carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes
of Health. The protocol was approved by the Institutional Animal Care and Use Committee at
the Icahn School of Medicine at Mount Sinai Center for Comparative Medicine (registration
number: D16-00069).
All procedures using rat serum were performed in strict accordance with guidelines set by
the National Institutes of Health (USA) and the Hungarian law on animal care and protection.
The protocol was first approved by the Institutional Ethical Committee for Animal Care and
Use of Semmelweis University and then approved by the Government Office of Pest County
Directorate of Food Chain Safety and Animal Health (registration number: PEI-001/3948-6/
2014).
Cell lines and recombinant proteins
Ecotin KO variants of E. coli BL21 (DE3) Star (Invitrogen), ATCC 12014 and ATCC 23505
were made according to [53]. Recombinant ecotin variants were expressed in E. coli BL21
(DE3) Star (ecotin KO) and purified to homogeneity. Recombinant enzymes were expressed
and purified according to [54,55]. SGMI-1, SGMI-2 and TFMI-3 were expressed and purified
as described in [14,21,56]. The KI values of ecotin variants against MASP-1 and MASP-2 were
determined on synthetic substrates. The KM values of MASP-1 and MASP-2 for Z-Lys-SBzl
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were determined (Fig 2). Complement activity was measured in C3-deposition ELISA assays
in 2% NHS as described in [13,27]. Similar tests were also conducted with mouse and rat
serum as well.
Reagents
All common laboratory reagents were from Sigma-Aldrich and Merck. High-binding microti-
ter plates were from Greiner Bio-One.
Construction of ecotin knockout E. coli strains
The ecotin gene of E. coli BL21 (DE3) Star (Invitrogen), ATCC 12014 and ATCC 23505
(American Type Culture Collection, ATCC) was replaced with the chloramphenicol acetyl-
transferase gene (EC 2.3.1.28) using the recombineering plasmid pKD46-RecA as described
[53,57]. The plasmid was electroporated into the bacteria, recombinant clones were isolated
and the loss of the heat-sensitive plasmid was verified. Successful replacement at the targeted
genomic locus was confirmed by PCR, restriction analysis and DNA sequencing using specific
primers. The chloramphenicol resistance gene was kept to serve as a stable selection marker
for the strains BL21 (DE3) Star ecotin KO, ATCC 12014 ecotin KO and ATCC 23505 ecotin
KO. No ecotin could be detected in the periplasm of the recombinant (ecotin KO) clones.
Construction of ecotin expression vectors
The gene coding for the mature E. coli ecotin sequence (UniProt: P23827) had originally been
cloned into the pT7-7 expression vector [17]. Genes coding for the mature ecotin protein
sequences of Y. pestis (UniProt: A4TNJ2), P. aeruginosa (UniProt: B7UZW2), and L. major
(corresponding to the ISP2 ecotin ortholog) (UniProt: Q4QFD4) were codon-optimized for
expression in E. coli. Cleavage sites of frequently used restriction endonucleases were removed
with silent mutations.
The four ecotin genes were obtained as a single synthetic construct (Life Technologies) in
which each variant was flanked by cleavage sites of two different restriction endonucleases.
The plasmid was digested with the appropriate enzymes in separate reactions. The genes were
isolated and amplified by PCR using specific primers that also incorporated NcoI and HindIII
sites. The genes of Y. pestis and P. aeruginosa ecotins were sub-cloned into the pET-25b(+)
periplasmic expression vector (Novagen) with NcoI and HindIII restriction endonucleases.
The L. major ecotin gene was sub-cloned into a modified pETM-11 cytoplasmic expression
vector with NcoI and HindIII restriction endonucleases. The L. major ecotin was produced
with an N-terminal His6-tag which could be cleaved off with TEV protease.
Expression and purification of SGMI-2, TFMI-3, pro-FD and the catalytic
fragments of MASP-1, MASP-2, MASP-3, C1s and C1r
SGMI-1, SGMI-2 and TFMI-3 were expressed and purified as described previously [14,21,56].
Active catalytic fragments of MASP-1, MASP-2, MASP-3, C1s and C1r containing the CCP1-
CCP2-SP domains were expressed and purified as described previously [22,54,55,58,59].
Expression, purification and processing of recombinant human pro-FD was done as described
previously [22].
Expression of ecotin orthologs
E. coli BL21 (DE3) Star ecotin KO cells were transformed with the expression vectors. Trans-
formed cells were grown in LB medium to OD600 nm = 4 at 37˚C. Recombinant protein
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expression was induced with 0.5 mM isopropyl-β-D-thiogalacto-pyranoside. After 5 hours, the
cell cultures were harvested via centrifugation (4500 g, 4˚C, 10 min).
Purification of E. coli, P. aeruginosa and Y. pestis ecotin orthologs
Cells were resuspended in 100 mL / liters of cell culture 2.5 mM MgCl2 and frozen at -20˚C
overnight. After thawing, the samples were centrifuged (48000 g, 4˚C, 20 min) and the super-
natants corresponding to the periplasmic fractions were sonicated to disrupt any residual cell
debris. Then, 65% (m/v) ammonium-sulphate was added gradually to the sample and the pre-
cipitated proteins were collected via centrifugation (48000 g, 4˚C, 20 min). The pellet was
resuspended in 2.5 mM HCl, and the sample was dialyzed against 2.5 mM HCl overnight at
4˚C. The dialyzed sample was centrifuged (48000 g, 4˚C, 20 min) and the pH of the ecotin-
containing supernatant was set to 7.9 with Tris base. The sample was loaded onto a GE HiTrap
Q HP anion-exchange column equilibrated with 10 mM Tris-HCl pH 7.9 buffer. In the case of
the Y. pestis ortholog, the ecotin was the major component of the flow-through. In contrast,
the E. coli and P. aeruginosa ecotin orthologs were retained by the column and were eluted
using a linear NaCl gradient. Fractions containing the ecotin orthologs were further purified
with RP-HPLC on a Phenomenex Jupiter 10u C4 300A column equilibrated with water, 0.1%
TFA, and eluted with a linear gradient of acetonitrile, 0.09% TFA. The ecotin containing frac-
tions were lyophilized and the proteins were dissolved in water.
Purification of His6-tagged L. major ecotin (ISP2)
The cells were resuspended in 100 mL per liter of cell culture 50 mM Na-phosphate, 300 mM
NaCl pH 7.5 buffer and the suspension was frozen at -20˚C. After thawing, the sample was
sonicated and centrifuged (48000 g, 4˚C, 20 min). The protein was purified on Bio-Rad Profi-
nity IMAC resin equilibrated with 50 mM Na-phosphate, 300 mM NaCl, pH 7.5. The protein
was eluted with the same buffer supplemented with 250 mM imidazole and dialyzed against 10
mM Na-phosphate pH 7.5 at room temperature. The His6-tag was cleaved off with His6-tagged
TEV protease. L. major ecotin was separated from the His6-tagged protease and the His6-tag
by a second Ni2+ affinity chromatography. The inhibitor was further purified on a GE HiTrap
SP HP cation-exchange column equilibrated with 10 mM Na-phosphate pH 7.5 buffer. The
protein was eluted with a linear NaCl gradient.
Quality control of the inhibitors
Purity of the proteins was confirmed via SDS PAGE. The correct molecular weight of the pro-
teins was verified via mass spectroscopy (ESI-MS).
Determination of the inhibitor concentration
Concentration of ecotin samples was determined similarly as described elsewhere [11]. Briefly:
bovine trypsin (Sigma Aldrich) was dissolved in 10 mM HCl, 10 mM CaCl2 and active-site
titrated using 4-methylumbelliferyl p-guanidinobenzoate [60]. The active concentration of
each ecotin stock was determined by titration against the active-site titrated trypsin. Incremen-
tal amounts of the inhibitors were incubated with 1 μM trypsin for 10 minutes in 50 mM Tris-
HCl pH 8.0, 10 mM CaCl2, 0.005% Triton X-100. Residual enzyme activities were measured
using 1 mM Nα-Benzoyl-DL-arginine p-nitroanilide. Inhibitor concentration was determined
by linear regression analysis.
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Equilibrium binding assays
The equilibrium inhibitory constant (KI) values of ecotin against the catalytic fragments of
MASP-1, MASP-2, MASP-3, C1s and C1r as well as against recombinant FD were determined
according to the method of Green and Work with the modifications of Empie and Laskowski
et al. [61,62]. The measurements were done in 20 mM HEPES, 145 mM NaCl, 5 mM CaCl2,
0.05% Triton X-100 pH 7.5 buffer in 200 μl final volume using a BioTek Synergy H4 multi-
mode microplate reader. A fixed concentration of protease was incubated with increasing
amounts of the inhibitor in separate samples. Enzyme concentrations were set based on pre-
liminary experiments. After reaching equilibrium, the amount of uninhibited enzyme was
quantitated using a thioester substrate combined with an appropriate co-substrate. In most
cases, 250 μM Z-L-Lys-SBzl hydrochloride thioester substrate and 500 μM 5,5’-dithiobis-
(2-nitrobenzoic acid) (DTNB) as photometric co-substrate were used. For C1s and C1r,
250 μM Z-Gly-Arg-SBzl was combined with 500 μM DTNB. For the tight-binding E. coli
ecotin / MASP-3 interaction the 250 μM Z-L-Lys-SBzl hydrochloride thioester substrate was
combined with 40 μM of the high-sensitivity Thiol Fluorescent Probe IV co-substrate. The
fluorescence of this co-substrate increases 470-fold upon reacting with thiols [63]. The KI val-
ues were determined from at least two parallel measurements by nonlinear regression analysis
in OriginPro software using the following equation:
E½ � ¼ ½E�
0
 
½E�
0
þ ½I�
0
þ KI  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ð½E�
0
þ ½I�
0
þ KIÞ
2
  4½E�
0
½I�
0
q
2
;
where [E], [E]0 and [I]0 represent the molar concentration of the free enzyme, the total
enzyme, and total inhibitor, respectively.
Based on the literature [7], a kon of 5.3 x 105 M-1 s-1 was used to estimate koff values and sub-
sequently the half-lives of the complexes. For enzyme-inhibitor pairs where the half-life of the
complex was comparable with, or shorter than the length of the measurements, only apparent
KI values (KI�) could be determined because there was a genuine competition between the
inhibitor and the substrate for enzyme-binding. The KI values were then calculated by the fol-
lowing equation:
KI ¼
KI
�
ð1þ ½S�=KMÞ
;
where [S] is the molar concentration of the substrate and KM is the Michaelis constant [64].
For this calculation, the KM values of the three MASPs for Z-L-Lys-SBzl were determined by
us. For FD, a KM of 3.79 mM, while for C1s, a KM of 190 μM was used, based on the literature
[65,66].
Determination of the KM values
The KM values of the three MASPs for Z-L-Lys-SBzl were determined in 20 mM HEPES, 145
mM NaCl, 5 mM CaCl2, 0.05% Triton X-100 pH 7.5 buffer in 200 μl final volume using a Bio-
Tek Synergy H4 multimode microplate reader. Initial reaction rates (V0) were measured at 410
nM for increasing Z-L-Lys-SBzl concentrations in samples containing 500 μM DTNB co-sub-
strate and 10 nM MASP-1, 30 nM MASP-2, or 5 nM MASP-3. Three parallel measurements
were done, V0 values were averaged and plotted as the function of [S]. The Hill-equation was
fitted to the data using the OriginPro software to obtain the KM values shown in Fig 2.
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Analysis of the interaction between E. coli ecotin and MASP-3 using pro-
FD as a substrate
These experiments were done as in [22] with the following modifications. The cleavage assays
were performed in 50 mM HEPES, 140 mM NaCl, and 0.1 mM EDTA pH 7.4 buffer. For pro-
ducing a free MASP-3 calibration curve for the subsequent experiments, samples with MASP-
3 concentrations in the 0–75 nM range were prepared and supplemented with pro-FD at
10 μM final concentration. The samples were incubated at room temperature for 40 min,
diluted 15-fold with ice-cold equilibration buffer (20 mM sodium phosphate, 70 mM NaCl pH
6.8), loaded onto a 4.6 × 50 mm YMC-BioPro SP-F nonporous high-pressure cation exchange
column (YMC Europe GmbH), and eluted with a 70–470 mM linear NaCl gradient in the
same buffer at 0.8 ml/min. For the analysis of MASP-3 inhibition by E. coli ecotin or TFMI-3
75 nM MASP-3 and increasing concentrations of the inhibitors were mixed and incubated
for 10 min or overnight at room temperature. 10 μM pro-FD (final concentration) was added
to the samples. After 40 min the reactions were stopped and the samples were analyzed as
described previously. Briefly, AUC values of the pro-FD and FD chromatographic peaks were
determined. Free MASP-3 concentrations in the enzyme:inhibitor samples were then calcu-
lated based on the above described calibration curve.
Cy3-labeled pro-FD cleavage in NHS
These experiments were done based on the already described method [22]. A total of 4 μl 1
mg/ml Cy3-labeled pro-FD was added to 40 μl NHS, and the mixtures were incubated at 37˚C
for 24 hours. Samples were withdrawn at every hour in the first 8 hours, at 10 h, 12 h and then
at 24 h on pro-FD conversion. The inhibitors were added to the serum samples at 1 μM final
concentration and incubated for 10 minutes prior to addition of the labeled pro-FD. The reac-
tion in the withdrawn samples was immediately stopped by 10-fold dilution with SDS-PAGE
sample buffer and heating for 2 min at 95 ˚C. A total of 2 μl of the cleavage assay samples con-
taining 18 ng Cy3-labeled protein were run on SDS-PAGE under reducing conditions. The
gels were scanned with a Typhoon laser scanner (GE Healthcare). Band intensities were quan-
tified by densitometry. Because the two bands were partially overlapping, only the time point
at which the intensity of the Cy3–pro-FD band equaled that of the Cy3-FD band could be reli-
ably determined on the gel, and this time point was considered as the half-life of Cy3– pro-FD.
Testing FD- and C3bBb-inhibiting capacity of ecotin in an in vitro AP
convertase generating system
An in vitro AP convertase generating system was set up by mixing 100 nM C3b, 30 nM FB and
1 μM C3 that served as substrate for the freshly generated C3bBb-type C3-convertase. This
mixture was pre-incubated in 50 mM Tris-HCl, 200 mM NaCl, pH 7.45 buffer at room tem-
perature, for 30 minutes without (positive control) or with inhibitors, before starting AP-con-
vertase generation by adding 10 nM FD. One of the samples contained 10 μM ecotin, while the
other contained 100 μM of the pan-specific serine proteinase inhibitor, FUT-175, that inhibits
all CS proteases. A sample containing neither FD nor FB served as negative control. From the
mixtures that received FD samples were withdrawn at various time points, and were immedi-
ately treated with mercaptoethanol and SDS containing gel loading sample buffer at 95 ˚C.
C3b-generation from C3 was assessed by SDS-PAGE. C3 and C3b were applied onto the gel as
controls. Extent of C3-cleavage and C3b-generation for the inhibitor containing samples were
compared to those in the positive control sample containing no inhibitor and to the samples
taken directly after starting the AP-convertase generation by adding FD. This way, we could
Ecotin protects bacteria against human serum-mediated lysis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008232 December 20, 2019 25 / 33
deconvolute the quantity of C3b added to enable the preliminary C3bB-formation from the
C3b generated by the convertase. The results were analyzed via ImageJ software.
Preparation of pooled NHS
Blood was drawn from 10 healthy donors after informed written consent into Vacutainer
serum tubes (BD Diagnostics) to produce fresh serum. Blood samples were incubated for 1 h
at room temperature to allow complete coagulation. The serum was collected, pooled, and
stored at −80 ˚C until use.
Preparation of pooled mouse serum
Blood was collected from five C57BL/6 and five BALB/c mice at the age of 6-10 weeks by veni-
puncture of the facial vein. Blood samples were incubated for 0.5 hours at room temperature
to allow coagulation to be completed. The samples were centrifuged at 14,000 rpm for 20 min-
utes at 4 ˚C. Serum supernatants were pooled, snap frozen in liquid nitrogen and stored at -80
˚C until use.
Preparation of rat serum
Blood was collected from an individual euthanized Wistar rat. The serum preparation was
done as described for human serum preparation.
Complement ELISA assays
Classical pathway (CP) inhibition measurements from NHS. CP activity was mea-
sured through detection of C3-deposition as described previously [27], with the following
modifications:
1. Greiner high-binding microtiter plates were coated with 10 μg/mL IgG in 15 mM Na2CO3
pH 9.6, and incubated overnight at 4 ˚C.
2. Wells were blocked with 1% BSA in TBS pH 7.4 for 1.5 hours at 37 ˚C, then washed with
TBS, 5 mM CaCl2, 0.1% Tween 20.
3. Pooled NHS was diluted 50-fold in 10 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 5 mM
MgCl2, 0.1% Tween 20, pH 7.4 (NHS buffer) containing serial dilutions of inhibitors.
4. These mixtures were pre-incubated in single loose tubes (National Scientific Supply Com-
pany) for 30 min at room temperature before transferring onto the activator surface.
Polyclonal rabbit anti-human C3c antibody (A0062; DakoCytomation) was used as the
primary antibody in 2000-fold dilution and HRP-conjugated anti-rabbit antibody (A1949,
Sigma) was used as the secondary antibody in 40,000-fold dilution.
The signal produced by non-inhibited NHS was considered to be 100% activity, while 0%
complement activity was defined as the signal produced by 2% NHS treated with 50 μM FUT-
175 inhibitor. Results were obtained from four parallel measurements. In all serum tests, the
signal developing reaction on the plate was stopped when optical density of the highest signal
intensity non-inhibited reaction was between OD 0.5–1.0. The typical background signal was
around OD 0.05.
Lectin pathway (LP) inhibition measurements from NHS. LP activity was measured
through detection of C3-deposition as described previously [27], with the following
modifications:
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1. Greiner high-binding microtiter plates were coated with 10 μg/mL mannan in 35 mM
NaHCO3, pH 9.6, and incubated overnight at 4 ˚C.
2. Wells were blocked with 1% BSA in TBS pH 7.4 for 1.5 hours at 37 ˚C, then washed with
TBS, 5 mM CaCl2, 0.1% Tween 20.
3. Pooled NHS was diluted 50-fold in 10 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 5 mM
MgCl2, 0.1% Tween 20, pH 7.4 (NHS buffer) containing serial dilutions of inhibitors.
4. These mixtures were pre-incubated in single loose tubes (National Scientific Supply Com-
pany) for 30 min at room temperature before transferring onto the activator surface.
Polyclonal rabbit anti-human C3c antibody (A0062; DakoCytomation) was used as the
primary antibody in 2000-fold dilution and HRP-conjugated anti-rabbit antibody (A1949,
Sigma) was used as the secondary antibody in 40,000-fold dilution.
The signal produced by non-inhibited NHS was considered to be 100% activity. 0% comple-
ment activity was defined as the signal produced by 2% NHS treated with 50 μM FUT-175
inhibitor. Results were obtained from four parallel measurements.
LP inhibition measurements from rat serum. In these tests, 60-fold diluted serum was
used, otherwise the experiments were performed as described above, because the anti-human
C3c polyclonal primary antibody cross-reacts with rat C3c. The signal produced by non-inhib-
ited serum was considered to be 100% activity. 0% complement activity was defined as the sig-
nal produced by 60-fold diluted rat serum treated with 50 μM FUT-175 inhibitor. Results were
obtained from four parallel measurements.
LP inhibition measurements from pooled mouse serum. Nunc MaxiSorp plates were
coated with 10 μg/mL mannan in PBS overnight at 4 ˚C. Wells were blocked with 5 mg/ml
BSA in TBS pH 7.4 and washed with TBS, 0.05% Tween-20 (wash buffer) subsequently. Pooled
mouse serum was diluted 60-fold in TBS, 5 mM MgCl2, 5 mM CaCl2, 0.05% Tween-20 con-
taining serial dilutions of E. coli ecotin. These mixtures were pre-incubated for 15 min at room
temperature before transferring 100-100 μl onto the plate. The plates were incubated at 37 ˚C
for 30 minutes and then washed with wash buffer. 100–100 μl HRP-conjugated goat anti-
mouse C3 IgG (Cappel #55557) diluted 5000-fold in TBS, 5 mg/ml BSA, 0.05% Tween-20 was
applied to the plates and incubated for 1 hour at room temperature. The plates were washed
and 100 μl/well TMB substrate (Sigma) was added to the wells. The reaction was stopped by
adding 50 μl/well 1 M HCl and the signals were read at 450 nm.
The signal produced by non-inhibited serum was considered to be 100% activity. 0% com-
plement activity was defined as the signal produced by serum treated with 50 μM FUT-175
inhibitor. Results were obtained from three parallel measurements.
Alternative pathway inhibition measurements from NHS. Alternative pathway assays
were carried out as described for the LP and CP inhibition measurements from NHS, but with
the following important modifications:
1. the plates were coated with 100 μg/mL zymosan or with 10 μg/mL LPS (Sigma Aldrich).
2. Modified NHS buffer: 10 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 10 mM EGTA and
wash buffer: TBS, 0.1% Tween 20, 10 mM EGTA were used to prevent Ca2+-dependent acti-
vation of the classical and lectin pathways.
3. The final dilution of NHS was 6-fold.
Calculation of the half maximal inhibitory concentration (IC50) values. IC50 values
were calculated with using OriginPro software. Data was fitted using the following dose
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response function:
y ¼ Amin þ
Amax   Amin
1þ 10ðlogIC50   ½I�Þ�p
where Amin and Amax represent the minimum and maximum of the fitted curve, respectively,
[I] is the inhibitor concentration, p is the Hill slope and y is the degree of C3 deposition.
Detection of C3-deposition on E. coli by flow cytometry
Flow cytometry was used to assess C3-deposition on E. coli cells. E. coli ATCC 23505, ATCC
23505 ecotin KO, ATCC 12014 and ATCC 12014 ecotin KO cells were cultured in peptone/
beef extract (P/BE) broth, as recommended on www.atcc.org. At OD600 nm = 0.5, cells were
chilled on ice, centrifuged and washed twice with 10 mM HEPES, 145 mM NaCl, 5 mM CaCl2,
5 mM MgCl2 pH 7.4 buffer (NHS-buffer). Cell density was measured, and 3.4 x 10
7 cells were
transferred into 1.5 mL microcentrifuge tubes and pelleted at 15,000 g. The cells were sus-
pended in 200 μL of either NHS or NHS-buffer (negative control) at appropriate dilution, and
incubated at 37 ˚C for 30 minutes. After incubation, cells were washed twice and suspended in
100 μl of 1/500 polyclonal rabbit anti-C3c antibody (A0062, DakoCytomation) or in 100 μL
NHS-buffer, mixed thoroughly and incubated at 37 ˚C for an hour. After washing the cells
twice, 100 μl of 1/2000 Alexa Fluor 488 conjugated polyclonal goat anti-rabbit IgG (A21206,
Invitrogen) was added to each sample and incubated at room temperature for 30 minutes in
dark. Samples were measured on a Beckman Coulter CytoFlex instrument using CytExpert
software. SSC threshold values were set to exclude most of debris, and to enable gating on bac-
terial populations, data from 20,000 cells in the bacteria gate were collected in each sample. All
buffers used in flow cytometry samples were filtered (0.22 μm filter), to exclude any contami-
nating particles in the SSC-FSC range of the bacteria. Data analysis was performed using
FlowJo software. Due to the intensive lysis altering the detected signal of opsonized cells (Fig
10), no statistical significance was calculated.
Detection of C5b-9 (MAC) deposition on E. coli by flow cytometry
Flow cytometry was used to measure C5b-9-deposition on the surface of E. coli cells. All steps
were the same as described above, except that mouse anti-C5b-9 antibody (A239, Quidel) was
used as the primary antibody and Alexa Fluor 647 conjugated rabbit anti-mouse antibody
(A21239, Invitrogen) as the secondary antibody. Pore formation was also evaluated via adding
propidium iodide (PI) as a DNA stain. The percentage of C5b-9/PI positive cells was deter-
mined. The sample preparation steps yielded some PI+ (single positive) cells, but as the per-
centage of this PI positive population was constant in all samples, it was considered as artifact,
and was thereby excluded from data analysis. Single C5b-9 positive cells were present only in
very low amounts, suggesting a transient state that would also turn PI positive upon longer
incubation.
Bactericidal tests in NHS and HIS
Bactericidal tests were conducted based on the method of Muschel et al. [67], with modifica-
tions. Cells were grown to mid-log phase (OD600 nm ~ 0.5) in P/BE broth, centrifuged, washed
in NHS-buffer, and their density was determined via measuring the optical density at 600 nm,
in Beckmann Coulter DU-7400 spectrophotometer. Cells were diluted in P/BE broth, then 2 x
107 cells were transferred to each test tube. NHS-buffer (control tubes), NHS or HIS (both
diluted in NHS-buffer) was added to reach the appropriate final serum concentration. In the
experiments testing the effects of exogenously added inhibitors, the serum was pre-incubated
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with the appropriate inhibitor for 30 minutes at room temperature. The cells were incubated
with serum at 37˚C for 1h, then cells from the sample tubes were inoculated into 20-fold excess
of fresh, serum-free P/BE broth. This dilution ceased complement activation and lowered the
concentration of cell debris that could have interfered with the subsequent optical density
measurements. After 5h of incubation, optical density (λ = 600 nm) of the samples was mea-
sured and compared to those of the control samples.
Complementation of the ecotin KO cells with E. coli ecotin provided on an
IPTG-inducible expression vector
Protecting role of ecotin was tested in complementation experiments. As the two E. coli strains
are not compatible with T7 promoter vectors, we sub-cloned the gene of wild type ecotin from
the original pT7-7 [17] vector into the pTFPI-D2-pro-lib [14] phagemid vector using NdeI
and XbaI restriction enzyme cleavage sites. The resulting vector, which allows for IPTG-induc-
ible periplasmic expression of ecotin, was named pTac.Eco. The correct sequence of the vector
was confirmed by DNS sequencing. Ecotin KO E. coli ATCC 23505 and ATCC 12014 cells
were transformed with the pTac.Eco vector by electroporation. We tested that in P/BE broth,
the untransformed cells and the transformed, non-induced cells grew with the same rate, and
this rate did not decrease up to a level of 50 μM IPTG added to the transformed cells. There-
fore, an IPTG concentration of 50 μM was used for ecotin expression induction in the above
described bactericidal tests. Ecotin level in the periplasmic fraction was determined as follows.
Wild type E. coli ATCC 23505 and ATCC 12014 cells, their ecotin KO versions, their ecotin
KO pTac.Eco-transformed but non-induced versions and their ecotin KO pTac.Eco-trans-
formed and 50 μM IPTG-induced versions were grown in P/BE broth up to OD600 = 1.0. The
periplasmic fraction was isolated similarly to the procedure described at the “Purification of E.
coli, P. aeruginosa and Y. pestis ecotin orthologs” section in the Materials and methods, but
in this case the pelleted cells were resuspended in 10 mL / 1 L culture ice cold dH2O and were
frozen. The isolated periplasmic fractions were then diluted to the same protein content based
on OD280 value with 20 mM Tris-HCl, 5 mM CaCl2, pH 7.9 buffer. Then, serial dilutions
of the buffered periplasmic fractions were mixed with 20 nM final concentration of bovine
chymotrypsin (Worthington, #LS001432) and incubated for 1 hour. Free residual enzyme
concentration was determined by 250 μM Suc-Ala-Ala-Pro-Phe-PNA substrate (Bachem AG,
#1067440).
Statistical analysis of results
Where statistical significance is indicated, two-tailed unpaired Student’s t-test was performed.
Difference between two tested datasets was considered significant if the calculated P value was
lower than 0.05.
Analyzing the phylogenic distribution of ecotin harboring organisms
Species were selected from the PFAM database [68] with the keyword „ecotin”. Only species
with proper identification were analyzed, isolates such as “Pseudomonas sp.” were excluded.
Multiplicates representing multiple entries/ecotin domains from the same microorganism
were removed. Ecotin-expressing species were considered pathogenic if they are listed in at
least one of the following databases: Global RPH (globalrph.com/bacteria), Bode Science Center
(www.bode-science-center.com/center/relevant-pathogens-from-a-z.html), or American Bio-
logical Safety Association (my.absa.org/Riskgroups). Number of species within individual phy-
logenic groups was looked up in the data of Catalogue of Life (www.catalogueoflife.org/col).
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